Velocity Clinical Research, Inc.

Craig Koch has been appointed Executive Vice President & General Manager, Europe, to lead the next phase of our expansion across the continent. With 17 dedicated research sites in Germany, Poland, and the U.K., Velocity is scaling its high-performance, centralized model to streamline clinical trials and enhance global patient access. As one of Velocity’s first employees and leaders, Craig has played a pivotal role in driving the company’s growth and operational scale. His appointment and relocation to Europe reinforces Velocity’s strong commitment to the region. As Craig put it: “We’ve built something different… The Velocity model improves efficiency, delivers reliable performance, and ultimately gets drugs to market faster. We’re now at a point where the barriers that once prevented companies from doing business in Europe are coming down. Speed and quality are of the essence, and we’re here to deliver both.” Read more: https://lnkd.in/gq2_Uc9S #ClinicalTrials #ClinicalResearch

World Obesity Day serves as a reminder of one of the most prevalent health challenges worldwide. Obesity affects approximately 40% of U.S. adults and is a major driver of related conditions such as diabetes, heart disease, and metabolic disorders — all of which are key areas of therapeutic focus for Velocity’s CARE Councils. As obesity rates continue to rise, particularly among younger populations, clinical research will be essential to shaping the future of obesity treatment, including GLP-1 agonists. Learn more about the Velocity Diabetes and Obesity CARE Council: https://lnkd.in/gAGgxcZa #WorldObesityDay #ClinicalResearch

Congratulations to our growing team in Hyderabad! Raghu Punnamraju and our team have just moved into a new office, marking another step forward in an exciting journey. What started as our technology hub has expanded with the addition of an operations group. VISION is the first comprehensive, AI-enabled technology platform built by sites, for sites. In mid-2023, it empowered the first participant to self-screen and self-schedule a study visit at Velocity. Today, VISION operates 24/7 across the U.S., Germany, Poland, and the U.K., setting a new standard for patient engagement and site productivity. A huge thank you to our team in India for their dedication and ingenuity. We’re excited for what’s ahead! #VelocityAtScale #AI

Brandon Essink, MD, CPI, is the lead author of study results exploring a next-generation flu vaccine for adults 50+. The published results highlight the potential for combining cell-based approaches and adjuvants to enhance immunogenicity relative to standard flu vaccines on the market. Title: “A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50?years and older.” Link: https://lnkd.in/gdWfJYp8 #Influenza #ClinicalTrials #Vaccines

In a recent study, Velocity randomized over 2,750 participants across 29 sites, including more than 200 at our High Wycombe, U.K., location. Explore more examples of Velocity’s performance at scale: https://lnkd.in/g7En6sbT #VelocityAtScale #ClinicalTrials #ClinicalResearch

What an incredible couple of days at SCRS Lisbon 2025! We’ve had amazing conversations, high energy, and a shared commitment to elevating Europe’s role in the global clinical trial landscape. While challenges remain, the motivation and willingness to drive real change were evident. Making Europe more attractive to sponsors and CROs is a key priority, and it’s clear that the industry is ready to take bold steps forward. A highlight of the conference was our networking event on Monday night, where we had a room full of sponsors and CRO partners coming together to connect, exchange ideas, and enjoy a fantastic evening. Looking forward to continuing these discussions beyond the conference and reconnecting in 12 months—hopefully celebrating the progress we’ve made! #SCRSLisbon2025 #ClinicalTrials #Collaboration #Innovation

Renata Berardocco, VP of Operations, Latin America, will be speaking at the Sociedade Brasileira de Profissionais em Pesquisa Clínica (SBPPC Pesquisa Clínica) National Meeting in S?o Paulo on March 21–22. This national gathering of clinical research professionals will explore key advancements shaping the future of research, particularly as it evolves in Brazil and across LATAM. Connect with Renata to learn more about Velocity’s presence in Brazil and throughout LATAM.

Before trials even begin, Velocity can accelerate your site selection processes by providing fast, accurate feasibility responses and a ‘one contact, one contract’ approach for all sites. Working at scale, Velocity has also driven 50% faster IRB review cycles compared to peers (includes submission, clarification, and approval timelines). Learn more about Velocity at Scale: https://lnkd.in/g7En6sbT #VelocityAtScale #ClinicalTrials

On your way to #SCRSEurope in Lisbon? Connect with Evelyne Mabouellet Newton, Rachael Buck, Ph.D, and Agnieszka Gackowska to talk about your trial!

In this edition of The Recap, Nick Spittal shares his insights from #SCOPESummit, where AI, trial efficiency, and multisite research took center stage. Also inside: ? Velocity is a founding member of the Association of MultiSite Research Corporations (AMRC). ? Notes on AI’s role in accelerating clinical trials. ? VISION’s latest recognition for enhancing trial accessibility. ? Velocity announces a partnership with Verified Clinical Trials to combat double enrollment. Tap or click below to read The Recap! #ClinicalTrials #AI #TheRecap #ClinicalResearch